45 results on '"Izumi, Takaaki"'
Search Results
2. Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection
3. The risk of weekend biopsy: Impact of specimen source and fixation status on HER2 assessment in the treatment of advanced gastric cancer (The HER_WEEKEND study)
4. Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment
5. Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation‐related hepatitis
6. Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy
7. A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma
8. Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment
9. Increased serum C‐reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of tolvaptan in patients with liver cirrhosis
10. Add‐on effects of fluvastatin in simeprevir/pegylated‐interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study
11. Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C
12. Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150
13. Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150
14. Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus‐infected patients with renal impairment
15. Hepatitis B virus X protein impairs α‐interferon signaling via up‐regulation of suppressor of cytokine signaling 3 and protein phosphatase 2A
16. Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon‐lambda 3 induction in chronic hepatitis B patients
17. Theds potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease
18. Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria
19. Combination of neutrophil-to-lymphocyte ratio and early des-γ-carboxyprothrombin change ratio as a useful predictor of treatment response for hepatic arterial infusion chemotherapy against advanced hepatocellular carcinoma
20. Assessing the risk of hepatocellular carcinoma by combining liver stiffness and the controlled attenuation parameter
21. FRI-195-Long-term effect of nucleos (t)ide analogs on hepatitis B surface antigen in chronic hepatitis B patients
22. Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis
23. L-Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis
24. Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis
25. L‐Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis
26. The relatives between physical properties of proton conductor oxide and electrode performances by adding materials to anode on solid oxide fuel cells
27. Examination of the CO2/H2O Electrolytic Reaction Mechanism Using a Solid Oxide Fuel Cell
28. Increased serum C‐reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of tolvaptan in patients with liver cirrhosis
29. Combination of neutrophil-to-lymphocyte ratio and early des-γ-carboxyprothrombin change ratio as a useful predictor of treatment response for hepatic arterial infusion chemotherapy against advanced hepatocellular carcinoma
30. The power generation characteristics using dry methane in the solid oxide fuel cell by adding La0.99Ca0.01NbO4 to the electrode
31. 固体酸化物燃料電池を利用したCO2/H2O電解反応機構の検討
32. ペロブスカイト型酸化物の燃料極添加による固体酸化物燃料電池の電気化学特性の変化
33. Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C
34. Hepatitis B: progress in understanding chronicity, the innate immune response, and cccDNA protection
35. Hepatitis B virus X protein impairs α-interferon signaling via up-regulation of suppressor of cytokine signaling 3 and protein phosphatase 2A
36. Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction.
37. Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection.
38. Influence of Reactions of Carbon Black and Fuel Diffusion Process on Power Generation Characteristics of Rechargeable Solid Carbon Fuel Cells(RSCFCs)
39. Effects of Preadsorbed H2O and CH4on H2and He Adsorption on Activated Carbon at Cryogenic Temperature
40. 1005 Diesel Combustion Characteristics of Emulsified Palm Oil Butyl Ester
41. C42 Diesel Combustion of Emulsion Fuels Produced from Various Palm Oil Esters
42. Phenyl- and Tolylthallium(III) Bis(trichloroacetate)s; Preparation and Reactions
43. Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases.
44. Investigation of the utility of various diagnostic guidelines for Wilson's disease.
45. A case report of a recurrent abscess secondary to fish bone penetration of the ileum.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.